A new class of vaccine adjuvants is “mast cell activators.”
However, in people with autism spectrum disorders, “Mast cell activation may contribute to gut-blood-brain barrier disruption and brain inflammation.”
But every vaccine and every adjuvant is equally safe for all people. No matter what. Right?
:sarcasm:
http://mastcellmaster.com/documents/Autism-Exp-Opinion-Pharmacoth-8-09.pdfAutism: an emerging ‘neuroimmune disorder’ in search of therapy
Theoharis C Theoharides†, Duraisamy Kempuraj & Lyn Redwood
†Tufts Tufts University School of Medicine, Department of Pharmacology and Experimental Therapeutics, Boston, Massachusetts, USA
Results/conclusion: Increased oxidative stress and immune dysregulation are present in ASDs. (Autism spectrum disorders) Mast- cell activation may contribute to gut–blood–brain barrier disruption and brain inflammation. No effective treatments have emerged.
SNIP
Much useful evidence has been produced over the last few years on ASDs <209>, but we now need to move from informational to transformational research if we are to develop novel effective treatments. Increased effort should be directed at understanding what might contribute to the pathogenesis of autism, rather than the neurological sequellae. Mast cells and CRH are involved in the regulation of BBB pathophysiology <139> and inflammation <105>. Enteroviruses, neuropeptides, stress hormones, and toxins could contribute through mast-cell activation, especially in subpopulations that are made vulnerable by their age and genetic make-up.
_________________________________________________________________________
http://www.nature.com/nm/journal/v14/n5/abs/nm1757.htmlArticle abstract
Nature Medicine 14, 536 - 541 (2008)
Published online: 20 April 2008 | doi:10.1038/nm1757
Mast cell activators: a new class of highly effective vaccine adjuvants
James B McLachlan1,5, Christopher P Shelburne1,5, Justin P Hart1, Salvatore V Pizzo1, Rajen Goyal1, Rhea Brooking-Dixon1, Herman F Staats1,2,3 & Soman N Abraham1,2,4
Abstract
. . . . Collectively, these results define the MC as an integral sensory arm of the adaptive immune system. Moreover, they highlight MC activators as a new class of vaccine adjuvants, capable of inducing protective antigen-specific immune responses through needle-free routes of administration.